News Quantified

RPRX – royalty pharma plc - class a ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]

Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

Royalty Pharma Declares Second Quarter 2024 Dividend

Royalty Pharma plc (NASDAQ: RPRX) had its price target lowered by analysts at Bank of America Co. from $40.00 to $38.00. They now have a "buy" rating on the stock.

Royalty Pharma plc (NASDAQ: RPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.

Form ARS Royalty Pharma plc For: Dec 31

Form DEFA14A Royalty Pharma plc

Form DEF 14A Royalty Pharma plc For: Jun 06

Form 144 Royalty Pharma plc Filed by: GG 1978 SICAF SIF S.A. - GG Strategic

Form 144 Royalty Pharma plc Filed by: MGG Strategic SICAF SIF S.A. - MGG Strategic

Top News Gainers

12/12 Repros Therapeutics Inc.® Announces Acquisition by Allergan plc 49.1%

12/15 Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours [Seeking Alpha] 7.0%

1/4 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 5.3%

1/30 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 2.3%

12/21 Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx 2.0%

12/29 Form SC TO-T REPROS THERAPEUTICS INC. Filed by: Allergan plc 0.9%

12/14 Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy [Seeking Alpha] 0.3%

1/19 Form SC 14D9/A REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. 0.2%

1/9 Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division 0.1%

12/12 REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout 0.0%

Top News Decliners

1/31 Form POS AM REPROS THERAPEUTICS INC. -6.9%

12/15 Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency -5.6%

11/20 Repros Therapeutics Inc. (NASDAQ: RPRX) had its price target lowered by analysts at S&P Equity Research from $0.49 to $0.39. -3.4%

1/26 BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene [Reuters] -1.3%

12/12 Form 8-K REPROS THERAPEUTICS INC. For: Dec 11 -0.8%

12/29 Form SC 14D9 REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.5%

1/2 BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics [Reuters] -0.3%

12/13 Form SC14D9C REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.2%

1/26 European advisory group backs seven medicines for approval, rejects Repros' enclomiphene [Seeking Alpha] -0.1%

1/5 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc -0.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day